CoChat

Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results

Faggiano, Antongiulio, Leboulleux, Sophie, Young, Jacques, Schlumberger, Martin, Baudin, Eric · 2006 · Clinical Endocrinology
Cited by 51

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Summary: Introduction It has been reported that the therapeutic threshold of mitotane, plasma level above 14 µg/ml, is achieved within 3–5 months after o,p'DDD treatment initiation in patients with adrenocortical carcinoma (ACC). Objective and design We evaluated pharmacokinetic and tolerance of a high‐dose schedule of pure o,p'DDD treatment given in 500‐mg tablets of mitotane (Lysodren, Bristol–Myers Squibb, HRA Pharma, Paris, France) in four patients with ACC and two patients with Cushing's syndrome‐related endocrine tumours. It was administered at a starting dosage of 3 g/day, which was rapidly increased to 6–9 g/day within 2 weeks according to digestive tolerance and then adjusted according to tolerance and plasma o,p'DDD monitoring. Patients were followed up until they reached the therapeutic threshold of mitotane, and toxicity was recorded. A relationship between o,p'DDD dose and plasma level was sought. Results The highest starting dosage given ranged between 6 and 9 g a day, during the first two weeks. The daily maintenance dose ranged 4·5–9 g during the next 2 weeks and 3–9 g by the second month of treatment. The therapeutic threshold was reached in all four patients who received o,p'DDD treatment for at least 1 month. Among these four patients, the toxic threshold (plasma mitotane level > 20 µg/ml) was even reached at 6 weeks of therapy in three patients. Grade 1, 2 or 3 toxicity was observed in 3, 2 and 1 patients, respectively. Toxicity resolved after reduction or discontinuation of o,p'DDD therapy. A significant linear correlation was found between plasma mitotane dose and plasma level. Conclusions These results suggest that a high‐dose o,p'DDD therapeutic schedule is feasible with an acceptable toxicity and may shorten the time required to reach the therapeutic schedule from 3–5 months to 4 weeks. These patients require a close follow‐up, combining clinical and plasma o,p'DDD level monitoring every second week. A confirmatory study is ongoing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2265.2005.02403.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 51

Metadata

Authors
Faggiano, A., Leboulleux, S., Young, J., Schlumberger, M., & Baudin, E.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2005-12
Volume
64
Issue
1
Pages
110-113
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W2157310187
Cited by
51
References
2
FWCI
0.88
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.